Evofem Biosciences Q1 sales edge up on higher pricing
Cummins Inc. CMI | 0.00 | |
Evofem Biosciences, Inc. EVFM | 0.00 |
Overview
US women's health pharma Q1 sales rose slightly yr/yr, net loss reversed prior yr profit
Company attributed sales growth to higher pricing and favorable gross-to-net ratios for both products
Company expanded global reach with new distribution agreement for SOLOSEC in Sub-Saharan Africa
Outlook
Evofem expects non-dilutive capital from MENA and Sub-Saharan Africa markets in 2026
Company says UAE regulatory review for PHEXX and SOLOSEC is ongoing
Result Drivers
HIGHER PRICING - Co said Q1 sales growth was primarily driven by higher WAC and more favorable gross-to-net ratios for both PHEXX and SOLOSEC
LOWER PHEXX SALES - Q1 PHEXX ex-factory sales fell due to high wholesaler purchases in December 2025 ahead of price hike
Company press release: ID:nBw84D28Za
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Sales |
|
$899,000 |
|
Q1 Net Income |
|
-$5.47 mln |
|
Q1 Income from Operations |
|
-$4.57 mln |
|
Q1 Pretax Profit |
|
-$5.47 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.